Response adaptive randomization procedures in seamless phase II/III clinical trials

ABSTRACT It is desirable to work efficiently and cost effectively to evaluate new therapies in a time-sensitive and ethical manner without compromising the integrity and validity of the development process. The seamless phase II/III clinical trial has been proposed to meet this need, and its efficient, ethical and economic advantages can be strengthened by its combination with innovative response adaptive randomization (RAR) procedures. In particular, well-designed frequentist RAR procedures can target theoretically optimal allocation proportions, and there are explicit asymptotic results. However, there has been little research into seamless phase II/III clinical trials with frequentist RAR because of the difficulty in performing valid statistical inference and controlling the type I error rate. In this paper, we propose the framework for a family of frequentist RAR designs for seamless phase II/III trials, derive the asymptotic distribution of the parameter estimators using martingale processes and offer solutions to control the type I error rate. The numerical studies demonstrate our theoretical findings and the advantages of the proposed methods.

[1]  D. Berry.  Bayesian Statistics and the Efficiency and Ethics of Clinical Trials , 2004 .

[2]  H. Schäfer,et al.  Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches , 2001, Biometrics.

[3]  Nigel Stallard,et al.  Point estimates and confidence regions for sequential trials involving selection , 2005 .

[4]  L. J. Wei,et al.  The Randomized Play-the-Winner Rule in Medical Trials , 1978 .

[5]  William F. Rosenberger,et al.  Optimality, Variability, Power , 2003 .

[6]  Atanu Biswas,et al.  Multi-treatment optimal response-adaptative designs for phase III clinical trials , 2011 .

[7]  Lu Wang,et al.  Implementing Optimal Allocation in Clinical Trials with Multiple Endpoints. , 2017, Journal of statistical planning and inference.

[8]  P. Thall,et al.  Practical Bayesian adaptive randomisation in clinical trials. , 2007, European journal of cancer.

[9]  Jianhua Hu,et al.  Optimal biased coins for two-arm clinical trials , 2008 .

[10]  Yong Zang,et al.  Adaptive clinical trial designs in oncology. , 2014, Chinese clinical oncology.

[11]  Michael Woodroofe,et al.  Central Limit Theorems for Doubly Adaptive Biased Coin Designs , 1995 .

[12]  Boris Freidlin,et al.  Design issues in randomized phase II/III trials. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Mark Chang,et al.  Adaptive Design Methods in Clinical Trials, Second Edition , 2011 .

[14]  L Shen,et al.  An improved method of evaluating drug effect in a multiple dose clinical trial , 2001, Statistics in medicine.

[15]  Richard Simon,et al.  Two-stage selection and testing designs for comparative clinical trials , 1988 .

[16]  J. Matthews,et al.  Randomization in Clinical Trials: Theory and Practice; , 2003 .

[17]  HansâHelge Müller,et al.  Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches , 2001 .

[18]  Jack Bowden,et al.  Unbiased Estimation of Selected Treatment Means in Two‐Stage Trials , 2008, Biometrical journal. Biometrische Zeitschrift.

[19]  R. Simes,et al.  An improved Bonferroni procedure for multiple tests of significance , 1986 .

[20]  Martin Posch,et al.  Testing and estimation in flexible group sequential designs with adaptive treatment selection , 2005, Statistics in medicine.

[21]  C. Rout,et al.  A Reevaluation of the Role of Crystalloid Preload in the Prevention of Hypotension Associated with Spinal Anesthesia for Elective Cesarean Section , 1993, Anesthesiology.

[22]  Ying Yuan,et al.  A Bayesian response‐adaptive covariate‐balanced randomization design with application to a leukemia clinical trial , 2011, Statistics in medicine.

[23]  James F. Troendle,et al.  Conditional estimation following a group sequential clinical trial , 1999 .

[24]  Feifang Hu,et al.  Asymptotic theorems of sequential estimation-adjusted urn models , 2006 .

[25]  P F Thall,et al.  A two-stage design for choosing among several experimental treatments and a control in clinical trials. , 1989, Biometrics.

[26]  Terry M. Therneau,et al.  Optimal two-stage screening designs for survival comparisons , 1990 .

[27]  Li-Xin Zhang,et al.  Asymptotic properties of covariate-adjusted response-adaptive designs , 2006 .

[28]  F. Hu,et al.  Interim analysis of clinical trials based on urn models , 2012 .

[29]  Feifang Hu,et al.  Efficient randomized-adaptive designs , 2009, 0908.3435.

[30]  J. Andersen,et al.  Clinical trial designs--made to order. , 1996, Journal of biopharmaceutical statistics.

[31]  D. Berry.  Adaptive clinical trials in oncology , 2012, Nature Reviews Clinical Oncology.

[32]  Nigel Stallard,et al.  Sequential designs for phase III clinical trials incorporating treatment selection , 2003, Statistics in medicine.

[33]  Frank Bretz,et al.  Confirmatory Seamless Phase II/III Clinical Trials with Hypotheses Selection at Interim: General Concepts , 2006, Biometrical journal. Biometrische Zeitschrift.

[34]  Mark Chang,et al.  Adaptive Design Methods in Clinical Trials , 2006 .

[35]  E. Hatano,et al.  Premedication with 20 mg dexamethasone effectively prevents relapse of extensive skin rash associated with gemcitabine monotherapy. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  H. Suryapranata,et al.  The Na(+)/H(+) exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial. , 2001, Journal of the American College of Cardiology.

[37]  K. Gabriel,et al.  On closed testing procedures with special reference to ordered analysis of variance , 1976 .

[38]  Allan R Sampson,et al.  Drop‐the‐Losers Design: Normal Case , 2005, Biometrical journal. Biometrische Zeitschrift.

[39]  Feifang Hu,et al.  ST ] 1 7 O ct 2 00 6 ASYMPTOTIC PROPERTIES OF COVARIATE-ADJUSTED ADAPTIVE DESIGNS , 2006 .

[40]  Nigel Stallard,et al.  Seamless phase II/III designs , 2011, Statistical methods in medical research.

[41]  R. Gesser,et al.  A seamless Phase IIB/III adaptive outcome trial: Design rationale and implementation challenges , 2015, Clinical trials.

[42]  Feifang Hu,et al.  Sequential monitoring of response-adaptive randomized clinical trials with sample size re-estimation , 2010, Journal of Statistical Planning and Inference.

[43]  Harold B. Sackrowitz,et al.  Two stage conditionally unbiased estimators of the selected mean , 1989 .

[44]  Margaret Sullivan Pepe,et al.  Conditional estimation after a two-stage diagnostic biomarker study that allows early termination for futility. , 2012, Statistics in medicine.

[45]  Frank Bretz,et al.  Adaptive Dunnett tests for treatment selection , 2008, Statistics in medicine.

[46]  Frank Bretz,et al.  Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology , 2009, Statistics in medicine.

[47]  F. Hu,et al.  Statistical inference of adaptive randomized clinical trials for personalized medicine , 2015 .

[48]  M Kieser,et al.  Combining different phases in the development of medical treatments within a single trial. , 1999, Statistics in medicine.

[49]  S. Pocock,et al.  Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. , 2009, Pulmonary pharmacology & therapeutics.

[50]  N Stallard,et al.  Optimal Adaptive Designs for Binary Response Trials , 2001, Biometrics.

[51]  C. Dunnett.  A Multiple Comparison Procedure for Comparing Several Treatments with a Control , 1955 .

[52]  Alessandra Giovagnoli,et al.  Compound optimal allocation for individual and collective ethics in binary clinical trials , 2010 .

[53]  P. Bauer,et al.  Evaluation of experiments with adaptive interim analyses. , 1994, Biometrics.

[54]  Jing Ning,et al.  Using short‐term response information to facilitate adaptive randomization for survival clinical trials , 2009, Statistics in medicine.

[55]  W. Brannath,et al.  Selection and bias—Two hostile brothers , 2009, Statistics in medicine.

[56]  Peter F Thall,et al.  Seamlessly Expanding a Randomized Phase II Trial to Phase III , 2002, Biometrics.

[57]  W. Rosenberger,et al.  The theory of response-adaptive randomization in clinical trials , 2006 .

[58]  T. Pawlik,et al.  Organizing a multidisciplinary clinic. , 2014, Chinese clinical oncology.

[59]  Feifang Hu,et al.  Implementing optimal allocation for sequential continuous responses with multiple treatments , 2009 .

[60]  Michael A. Proschan,et al.  A Unified Theory of Two-Stage Adaptive Designs , 2002 .

[61]  William F. Rosenberger,et al.  Implementing Optimal Allocation in Sequential Binary Response Experiments , 2007 .

[62]  Frank Bretz,et al.  Adaptive designs for confirmatory clinical trials , 2009, Statistics in medicine.

[63]  Jack Bowden,et al.  Conditionally unbiased and near unbiased estimation of the selected treatment mean for multistage drop-the-losers trials , 2013, Biometrical journal. Biometrische Zeitschrift.

[64]  Nigel Stallard,et al.  Conditionally unbiased estimation in phase II/III clinical trials with early stopping for futility , 2013, Statistics in medicine.

[65]  Douglas E. Faries,et al.  A Case Study of an Adaptive Clinical Trial in the Treatment of Out-Patients with Depressive Disorder , 1994 .

[66]  Frank Bretz,et al.  Confirmatory Seamless Phase II/III Clinical Trials with Hypotheses Selection at Interim: Applications and Practical Considerations , 2006, Biometrical journal. Biometrische Zeitschrift.

[67]  Hongjian Zhu.  Statistical inference for response adaptive randomization procedures with adjusted optimal allocation proportions , 2017, Journal of biopharmaceutical statistics.

[68]  Atanu Biswas,et al.  Bayesian Adaptive Biased‐Coin Designs for Clinical Trials with Normal Responses , 2005, Biometrics.

[69]  Deepak L. Bhatt,et al.  Adaptive Designs for Clinical Trials. , 2016, The New England journal of medicine.

[70]  Jack Bowden,et al.  Unbiased estimation in seamless phase II/III trials with unequal treatment effect variances and hypothesis‐driven selection rules , 2016, Statistics in medicine.

[71]  W F Rosenberger,et al.  A COMPARISON OF URN DESIGNS FOR RANDOMIZED CLINICAL TRIALS OF K > 2 TREATMENTS , 2000, Journal of biopharmaceutical statistics.

[72]  John Whitehead,et al.  Estimation following selection of the largest of two normal means. Journal of Statistical Planning and Inference 138, 1629-1638. , 2008 .

[73]  Feifang Hu,et al.  Asymptotic properties of doubly adaptive biased coin designs for multitreatment clinical trials , 2003 .